CEG works with GSK to clear without conditions the acquisition of Astra Zeneca's analgesic brands

Friday, 3 April 2009

CEG partners Nils von Hinten Reed, Paul Muysert and Barbara Veronese advised GlaxoSmithKline on the acquisition of a portfolio of Astra Zeneca's analgesic brands which are predominantly sold in the Nordic region.  After an in-depth investigation in which CEG presented papers on unilateral effects and efficiencies to the Swedish Competition Authority, the transaction has been cleared with no conditions.